SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rolfe Lindsey

(Last)

(First)

(Middle)

C/O CLOVIS ONCOLOGY, INC.,

2525 28TH STREET, SUITE 100

(Street)

BOULDER

80301

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2015

3. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [ CLVS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee stock option (right to buy)	⁽¹⁾	04/07/2020	Common Stock	31,034	$3.08	D
Employee stock option (right to buy)	⁽²⁾	03/01/2021	Common Stock	17,241	$3.28	D
Employee stock option (right to buy)	⁽³⁾	03/01/2022	Common Stock	30,000	$24.74	D
Employee stock option (right to buy)	⁽⁴⁾	03/01/2023	Common Stock	40,000	$21.81	D
Employee stock option (right to buy)	⁽⁵⁾	01/10/2024	Common Stock	17,500	$73.98	D
Employee stock option (right to buy)	⁽⁶⁾	02/27/2024	Common Stock	35,000	$78.38	D
Employee stock option (right to buy)	⁽⁷⁾	03/02/2025	Common Stock	12,500	$79.05	D
Employee stock option (right to buy)	⁽⁸⁾	08/03/2025	Common Stock	35,000	$85.65	D

Explanation of Responses:

1. The option vested as to 25% of the shares on April 1, 2011 and the remainder vested in substantially equal installments over the 36 months immediately following such date.

2. The option vested as to 25% of the shares on March 1, 2012 and the remainder vested in substantially equal installments over the 36 months immediately following such date.

3. The option is immediately exercisable as to both vested and unvested shares. The option vested as to 25% of the shares on March 1, 2013 and the remainder vest in substantially equal installments over the 36 months immediately following such date. To the extent the reporting person exercises the option as to unvested shares, the reporting person will receive restricted shares that will vest in accordance with the vesting schedule for the option.

4. The option vested as to 25% of the shares on March 1, 2014 and the remainder vest in substantially equal installments over the 36 months immediately following such date.

5. The option vested as to 25% of the shares on January 10, 2015 and the remainder vest in substantially equal installments over the 36 months immediately following such date.

6. The option vested as to 25% of the shares on February 27, 2015 and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.

7. The option shall vest as to 25% of the shares on March 2, 2016, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.

8. The option shall vest as to 25% of the shares on August 3, 2016, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.

Remarks:

Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance

	/s/ Lindsey Rolfe	08/13/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.